Pay in 4 interest-free payments of $6.25 Learn more
Ships within 48 hours · Estimated delivery Aug 20 - Aug 25
This provides an adequate window for the capsule to pass through the stomach and reach the small intestine for optimal absorption before food is introduced
Ohtani, M
They have saved my life
Why this trial matters: First large Phase III evidence of biopsy-confirmed histologic benefit with a metabolic drug in MASH Demonstrates semaglutides impact beyond weight loss to disease-modifying liver effects Supports expanding GLP-1 therapeutics into liver disease care amid a high unmet need Ianalumab Meets Endpoints in Phase III Sjgrens Disease Trials (NEPTUNUS-1 & 2) Novartis reported that both Phase III studies of ianalumab achieved their primary endpoints in patients with Sjgrens disease, offering the first targeted therapy with statistically significant disease activity reduction in this chronic autoimmune disorder
